Status:
UNKNOWN
The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy
Lead Sponsor:
Hamamatsu University
Collaborating Sponsors:
Oita University
Conditions:
Helicobacter Pylori
Eligibility:
All Genders
15-90 years
Phase:
PHASE2
PHASE3
Brief Summary
FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is a...
Detailed Description
H. pylori -positive patients older than 15 years of age with gastritis, gastric ulcer, duodenal ulcer, or gastroduodenal ulcer are invited to participate in the study. These patients had endoscopicall...
Eligibility Criteria
Inclusion
- H. pylori-positive patients who have never undergo the H. pylori eradication therapy -
Exclusion
- Patients not infected with H. pylori, Patients who are allergic to amoxicillin, clarithromycin, lansoprazole, 13C-urea, or milk casein
- \-
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00281047
Start Date
January 1 2006
End Date
May 1 2006
Last Update
January 27 2006
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Oita Kouseiren Tsurumi Hospital
Beppu, Oita Prefecture, Japan, 874-8585
2
University Hospital of Oita University Faculty of Medicine
Ōita, Oita Prefecture, Japan, 879-5593
3
Senoo Clinic for Internal Medicine and Gastroenterology
Hamamatsu, Shizuoka, Japan, 431-3125
4
University Hospital of Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-3192